80:oral Is there something special about rare diseases? Examining societal preferences for exempting orphan drugs from cost-effectiveness criteria for reimbursement
80:oral Is there something special about rare diseases? Examining societal preferences for exempting orphan drugs from cost-effectiveness criteria for reimbursement